Deficiency of the GPIbα cytoplasmic tail greatly decreases tumor cell‐induced platelet activation by regulating PKC activation, and the inhibition of PKCα‐dependent platelet activation by pharmacological inhibitors or genetic ablation of PKCα attenuates hematogenous metastasis. The gene discussed is PRRT2; the disease is neoplasm.